AC Immune

Neurons
#AC Immune #Immunotherapy #Neuroscience #Parkinson's #US Food and Drug Administration (FDA)

Immunotherapy for Parkinson’s gets FDA Fast Track Designation

AC Immune has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for its anti-alpha-synuclein (a-syn) active immunotherapy candidate, ACI-7104, for the treatment of early-stage Parkinson’s disease (PD).  ACI-7104 is designed to induce a-syn-specific antibodies, preferentially recognising aggregated… Read More

#Editor's Choice #News #Regulatory

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

DDW Highlights: 14 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Eli… Read More

#Podcasts

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

This week in Drug Discovery (6 – 10 April) 

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.  This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.  The top stories: … Read More

#News

Lilly Biotechnology Center
#AC Immune #Alzheimer's #Eli Lilly

AC Immune and Lilly reach agreement on drug collaboration 

Biopharmaceutical company AC Immune has reached an amended agreement with Eli Lilly for the development of an Alzheimer’s treatment.  The amendment to the 2018 license includes an agreement on the collaboration to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative… Read More

#Business & Investment #News

#AC Immune #Alzheimer's #Immunotherapy #Parkinson's

Are active immunotherapies the key to Alzheimer’s disease?

Andrea Pfeifer, Co-Founder and CEO of AC Immune, examines how active immunotherapies could lead to a better treatment of Alzheimer’s disease.   Alzheimer’s disease is still, after so many decades, one of the greatest public health challenges. It affects millions of patients and their families, with an annual global cost that is… Read More

#Exclusive Content

Alpha-synuclein protein aggregate
#AC Immune #Immunotherapy #Neuroscience #Parkinson's #Phase II trial

Immunotherapy for Parkinson’s induces positive responses

AC Immune has announced additional interim safety and positive immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056, its anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease (PD).  Dr Andrea Pfeifer, CEO of AC Immune, commented: “We continue to be encouraged by the data… Read More

#News

Neurons in a brain with Alzheimer's disease
#AC Immune #Alzheimer's #FDA #Immunotherapy #Neurodegenerative disorders

FDA fast-tracks immunotherapy for Alzheimer’s disease

AC Immune has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease (AD). This follows FDA clearance of the Investigational New Drug (IND) application enabling expansion to the USA of the ongoing Phase… Read More

#Editor's Choice #News #Regulatory